Ultrasensitive Single Extracellular Vesicle Detection Using High Throughput Droplet Digital Enzyme-Linked Immunosorbent Assay

Zijian Yang, Yasemin Atiyas, Hanfei Shen, Michael J. Siedlik, Jingyu Wu, Kryshawna Beard, Gennadiy Fonar, Jean Pierre Dolle, Douglas H. Smith, James H. Eberwine, David F. Meaney, and David A. Issadore*

ACCESS

ABSTRACT: Extracellular vesicles (EVs) have attracted enormous attention for their diagnostic and therapeutic potential. However, it has proven challenging to achieve the sensitivity to detect individual nanoscale EVs, the specificity to distinguish EV subpopulations, and a sufficient throughput to study EVs among an enormous background. To address this fundamental challenge, we developed a droplet-based optofluidic platform to quantify specific individual EV subpopulations at high throughput. The key innovation of our platform is parallelization of droplet generation, processing, and analysis to achieve a throughput (~20 million droplets/min) more than 100x greater than typical microfluidics. We demonstrate that the improvement in throughput enables EV quantification at a limit of detection = 9EVs/μL, a >100x improvement over gold standard methods. Additionally, we demonstrate the clinical potential of this system by detecting human EVs in complex media. Building on this work, we expect this technology will allow accurate quantification of rare EV subpopulations for broad biomedical applications.

KEYWORDS: extracellular vesicles, droplet microfluidics, digital assays, diagnostics, microfluidics, parallelization

Extracellular vesicles (EVs) are a diverse set of lipid bound nanomaterials, which can be found circulating in blood and carry various molecular cargo that can be representative of their cells of origin.2,3 EVs have been discovered to play an important role in intercellular communication5 and to have enormous potential as biomarkers for a wide range of biomedical applications.5−11 Because EVs are heterogeneous, there has been an effort to measure EVs with single particle resolution. This technological push is analogous to the development of single cell analysis that fueled biological discovery in the past decade.12−16 Many of the proposed techniques are based on imaging.17−26 While imaging has been successful in resolving individual EVs, it is fundamentally limited to a number of particles (<10⁶) several orders of magnitude less than the quantity of EVs found in clinical samples (10¹⁰ EVs/mL, 10⁸ EVs in 10 μL of plasma).27 Digital droplet techniques, where single EVs are loaded into droplets and either barcoded for downstream next generation sequencing (NGS) analysis or digital enzyme-linked immunosorbent assay (dELISA) based fluorescence detection, have been particularly successful in addressing this challenge.22−25 However, a single platform has been unable to achieve the sensitivity to detect individual EVs, the specificity to distinguish particular EV subsets based on surface protein expression, and achieve throughputs relevant to study rare EV subpopulations.

In this work, we developed a high throughput digital assay to quantify rare EV subpopulations based on their expression of surface proteins among a large background of EVs26−28 (Figure 1A). We call our approach droplet-based extracellular vesicle analysis (DEVA). DEVA’s ultrasensitivity and robustness to complex background comes primarily from two interrelated aspects of the technology. (a) The multiple proteins expressed on a targeted EV surface allows for specific capture and labeling on microbeads. Due to this specificity, <0.03% of our beads resulted in a false positive signal, 8−40X lower than typical dELISAs26−28 (Table S1). (b) At such a low false positive rate, we found that our limit of detection (LOD) was Poisson noise constrained until the bead number was increased to N_bead = O (10⁶), which corresponded to N_drop = O (10²) to
ensure a digital distribution of beads within droplets (Table S2). Accordingly, we developed a platform to measure beads at a high throughput (∼20 million droplets/min) by parallelizing droplet generation, processing, and analysis, achieving a throughput >100× greater than typical in microfluidic systems using only accessible optics (<$1000) and soft-lithography fabrication. We evaluated our technology by first quantifying human neuron derived EVs spiked into PBS and achieved a LOD = 9 EVs/μL, a >100× improvement over standard single EV characterization methods. Moreover, we directly

Figure 1. High-throughput DEVA. (A) Detecting specific EVs at single particle level is challenging, as there exists enormous EV background (10^8) in just 10 μL of human plasma. (B) Bead-based digital ELISA assay for single specific EV detection. (i) Paramagnetic, fluorescent beads are coated with capture antibody. (ii) Antibody-coated beads are added to a sample containing target and background EVs. (iii) After bead–EV incubation, unbounded EVs are washed away. (iv) Biotinylated detection antibody is added to label the captured EVs. (v) Streptavidin–HRP is then added to bind to the biotinylated detection antibody and form an enzyme-labeled immunocomplex. (vi) The beads are mixed with HRP substrate and then partitioned into droplets. Droplets that contain an immunocomplex become fluorescent due to enzyme–substrate reaction. (C) (i) Miniaturized microfluidic platform for DEVA that integrates droplet generation, incubation, and detection. (ii) All droplets flow through a delay line chamber for incubation. Afterward, all droplets flow through a detection section consisting of 90 parallelized microfluidic channels. (iii) A parallelized flow focusing droplet generator encapsulates the beads into droplets. (iv) The EV–bead immunocomplex turns the droplet fluorescent during the incubation in the delay line. (v) A machine vision camera records the encoded fluorescent signal of 90 parallelized microfluidic channels and transfers the video to cloud computation for image analysis. S is short for substrate while B is short for beads. S|B+: a droplet expresses signal from both substrate and bead. S|B−: a droplet only contains bead signal. S−B+: a droplet expresses signal from both substrate and bead.
demonstrated the importance of the throughput of our system by showing that the LOD of DEVA improved with an increase in the number of beads up to $10^6$ beads. Additionally, we evaluated the potential of this system for use in clinical samples by quantifying human neuron EVs spiked in complex media with a background of EVs matched to that of 2 μL of human blood and found an LOD = 11 EVs/μL.

### SINGLE EV DETECTION ON DEVA

Our DEVA assay uses fluorescent paramagnetic microbeads ($d = 5.4 \mu m$) functionalized with a capture antibody to target EV subpopulations based on their expression of a particular surface protein (Figure 1B). We label the beads with a fluorescence signal for two key reasons. First, it allows us to calculate the ratio average EV per bead (AEVB) accurately without having to make an assumption about the number of beads that have flowed through our system. Second, it provides a convenient means to multiplex our system, wherein the color of the microbead can indicate the capture antibody. The microbeads are first incubated with the sample to capture target EVs. After magnetic separation and washing, captured EVs are labeled with a biotinylated labeling antibody, followed by a streptavidin-HRP enzyme, to form an enzyme-linked immunocomplex. After washing to remove unbound antibodies and enzyme, the beads are mixed with a fluorescence enzyme substrate (ThermoFisher) and loaded into $d = 20 \mu m$ aqueous droplets suspended in oil (Bio-Rad) using parallelized droplet generators (Figure 1C). The droplets are incubated for 5 min on-chip to allow the immunocomplexes to generate a fluorescent signal. A fluorescent droplet corresponds to a single EV that is positive for both the protein targeted by the capture antibody and the labeling antibody. Each droplet is inspected using our microdroplet megascale detector (μMD) platform in two fluorescence channels, one channel to determine whether the droplet contains a fluorescent bead and the other to interrogate if the droplet is fluorescent. The ratio of beads that have captured an EV versus the total number of beads is the AEVB. To ensure the assay is in the digital regime, that is, there is one or zero EVs per bead and one or zero beads per droplet, we use >10× as many beads as EVs and >10× as many droplets as beads.

We perform high throughput fluorescence detection using a digital camera by modulating the light sources in time with a pseudorandom sequence at a rate >10× the frame rate of the camera, encoding the droplet streak with a pattern that allows it to be resolved using correlation based detection among neighboring droplets. Downstream of the delay line, droplets flow through a detection region that consists of 90 parallelized
microfluidic channels, where their fluorescence is measured using two time-domain modulated laser diodes and a machine vision camera (Grasshopper) (Figures 1C, S1). In this implementation, a blue laser and a green laser module ($\lambda_{\text{exBlue}} = 457 \text{ nm}, \lambda_{\text{exGreen}} = 528 \text{ nm}, \text{Techhood}$) were each modulated by an independent pseudorandom sequence, provided by a microcontroller (Arduino), to excite the fluorophores on microbeads and HRP substrate, respectively. Each pseudorandom sequence was an algorithmically generated 63-bit maximum length sequence (MLS), chosen to be minimally autocorrelated with itself and cross correlated with one another. Videos from the camera are processed by either a local computer or on the cloud.

THE BENEFIT OF HIGH THROUGHPUT DIGITAL EV DETECTION

We found that increasing the number of beads until $N_{\text{bead}} = \Theta(10^6)$ was a key factor in achieving the LOD and the dynamic range (DR) of our DEVA platform. The LOD of a digital ELISA is a function of both the background level $\text{AEVB}_b$ and the standard deviation $\sigma_{\text{AEVB}_b}$ across independent measurements of the background level, such that $\text{LOD} = \text{AEVB}_b + 3\sigma_{\text{AEVB}_b}$. We were able to achieve a background level of $\text{AEVB}_b = 2.6 \times 10^{-4}$ compared with that in typical digital ELISA ($AEB_b = [2 \times 10^{-3}, 2 \times 10^{-2}]$) (Table S1). With such a low false positive rate, if we had used 25 000 beads, as is typical in digital assays, we would only measure $N_b = 7$ false positive events. With only seven false positive events, the $\sigma_{\text{AEVB}_b}$ of the background level from shot noise alone is $\sigma_{\text{AEVB}_b} = \sqrt{\frac{N_b}{N_b}} = 38\%$, which would dominate the LOD if we assume the operational variance between experiments was $\sigma_{\text{exp}} = 5\%$. Given the dependence of the variance of $\text{AEVB}$ on the number of beads $N_{\text{bead}}$, the LOD can be improved by increasing the number of beads in an experiment until Poisson noise is no longer greater than the operational variance (Figure 2A). As conventional bead-based digital ELISA detects beads within wells on a statically micromachined chip, the total number of beads in an
experiment is usually between several thousands to tens of thousands,22,26,32,33 which fundamentally sets the background level AVEBb to be ∼0.2%, below which it would make no further improvement to the LOD. For our platform, we found that LOD could be improved by increasing beads up to \( N_{\text{bead}} = \mathcal{O}(10^6) \), resulting in \( N_{\text{drop}} = 2 \times 10^7 \) (Figure 2B). To process \( N_{\text{drop}} = 2 \times 10^7 \) at typical throughputs of flow cytometers or microfluidic systems \( \phi_{\text{typ}} = 1 \times 10^3 \text{ droplet/sec} \), it would take approximately 5 h to process a single experiment.

In addition to improving LOD, increasing the bead number also improves the dynamic range (DR) of DEVA. The upper value of the DR of a digital assay is limited by partitioning error \( \varepsilon_p \), which becomes significant when the number of EVs becomes similar to the number of beads \( N_{\text{bead}} \sim N_{\text{EV}} \) making it increasingly probable that there will be more than one EV bound to each positive bead (\( \lambda > 1 \), \( \lambda \) is the average number of EVs per bead). This partitioning error \( (\varepsilon_p) \) is modeled based on the binomial process and expressed as \( \varepsilon_p = \frac{1}{2} \ln \left( \frac{1}{1 + \frac{N_{\text{bead}}}{N_{\text{EV}}} e^{1/2}} \right) \) where \( Z_\varepsilon = 1.96 \) for 95% confidence interval and \( \sigma_E = \sqrt{\frac{e^{-\lambda} (1 - e^{-\lambda})}{N_{\text{bead}}} (\text{Figure 2C})} \). Incorporating more beads into our assay thus improves the LOL by keeping partitioning error low (\( \varepsilon_p < 10\% \) of final readout) for increasing quantities of target EVs (Figure 2D). Leveraging our system’s high throughput to measure large numbers of beads, both the LOD and the LOL can be improved, resulting in an expanded dynamic range for target EVs. From a user’s perspective, if the number of EVs falls below the LOD or over the LOL, the system would report accordingly.

### MICROFLUIDIC INTEGRATION OF OUR HIGH THROUGHPUT BEAD ANALYSIS

Building on our previous work on high throughput detection of droplets using time-domain-encoded optofluidics,10 we developed a high throughput single EV analysis platform by parallelizing droplet generation, processing, and analysis to achieve a throughput >100× greater than typical in microfluidic systems (Figure 1C). We updated our previous platform to be applied to DEVA in two main aspects. First, we used a
of evolving traumatic brain injury pathology, along with other processes help create the neurodegenerative microenvironment. 38

The velocity of the droplets and exposure time of our camera (45 ms) is chosen to generate a 63-bit MLS pattern in each droplet’s image streak length of 5 mm, which can be resolved by our optical system that has a resolution of 30 μm. A threshold is chosen to identify beads and positive droplets from the correlation signal of both the bead and the substrate fluorescence channel, by choosing a threshold that equals three standard deviations above the noise floor in the correlation signal. Additionally, we analyze the fluorescence signal of droplets with beads versus those without, and droplets with an enzyme versus those without, in Figure S3. We find that we can separate droplets with beads versus those without with an AUC = 1 (N = 41 droplets) and droplets with and without enzyme with an AUC = 1 (N = 118 droplets). Further details of our multidimensional correlation analysis were reported previously.39 An example of raw imaging data, and the corresponding correlation analysis, of a typical signal of a droplet containing a microbead that has and has not captured a single EV is shown in Figure 3E. To characterize this approach, we spiked known quantities of fluorescent microbeads into our detection platform and quantified the number of measured beads (Figure S3) (R² = 0.989). To match the throughput of our fluorescence detection, we integrated high throughput droplet generation (20 million droplets/min, d = 19.5 μm) by parallelizing 10 flow focusing droplet generators onto a single chip (Figure S4). We used a three-dimensional ladder geometry to uniformly distribute fluids to each droplet generator and collect each generator’s output.35

DEVELOPMENT AND CHARACTERIZATION OF ASSAY CONDITIONS FOR ULTRASENSITIVE SINGLE EV DETECTION

As a model system to evaluate DEVA, we used EVs isolated from a human neuronal cell line37 (S1). From this cell culture media, we isolated EVs using a commercial total-exosome isolation kit (ThermoFisher). We chose human neuron-derived EVs because neuronal EVs participate in neuron-glial communication, neuroinflammation, and propagation of pathogenic proteins such as amyloid-beta.38–40 These processes help create the neurodegenerative microenvironment of evolving traumatic brain injury pathology, along with other chronic neurologic disease pathologies.7 Moreover, as EVs can cross the blood-brain-barrier while remaining intact, they have great potential as biomarkers to monitor central nervous system injury and recovery.41

We characterized the EVs from this model system using scanning electron microscopy (SEM), nanoparticle tracking analysis (NTA), and Nanoview, which is a commercial platform for EV concentration, phenotype, and biomarker colocalization analysis. SEM demonstrated that, qualitatively, our antibody functionalyzed magnetic microbeads were capturing single EVs (Figures 4A, S5). NTA analysis was used to quantify the concentration of our cell culture derived EVs (1.4 × 10⁶ EV/mL) and their size distribution (d = 155 nm) (Figure 4B). We used Nanoview to determine which antibody to use to capture and to label EVs in our model system. With Nanoview, we quantified the heterogeneous protein expression on the EVs’ surface. In this assay, EVs are first captured on antibody-coated chips, then labeled with antibodies (CD9/CD63/CD81) conjugated with different fluorophores (Figure 4C). By quantifying the fluorescent events in each channel, we found that CD81 showed significant higher expression than CD63 or CD9 on our human neuron derived EVs (p < 0.05, p < 0.0001), which was also significantly higher than the IgG negative control (p < 0.001). Hence, we chose to functionalize our beads with anti-CD81 as capture antibody in DEVA. After EV capture, we used 1% SDS to lyse the captured CD81+ EVs and compared their protein cargo to the total EV input. The result showed 11% (9.6–12.4%) of all EVs expressed at least one CD81 marker on their surface (Figure S6). Among CD81+ EVs, we found that 67% (64.3%–69.8%) of EVs coexpressed another copy of CD81 that could be labeled with a fluorophore-conjugated antibody. Consistent with the observation of others, we found heterogeneity among EVs’ surface protein “pan-EV” markers even though they were derived from the same cell line.18,42,43

We chose to use CD81 for capture and labeling, rather than neuron specific surface markers, because this protein could be characterized using established Nanoview assay kits, allowing us to quantify and benchmark the performance of DEVA. Improving the performance of DEVA assay required optimization in a multidimensional parameter space, including the concentration of several reagents and blocking conditions. For instance, we evaluated the concentration of the labeling antibody and HRP enzyme to balance trade-off between nonspecific and specific labeling (Figure S7). The concentration of labeling antibody (6.6 nM) and HRP (1 nM) achieved the current performance that allowed us to validate our technology, and we believe that even better performance may be possible by further optimization.

EVALUATION OF THE PERFORMANCE OF DEVA FOR SINGLE EV ANALYSIS

We initially evaluated the performance of DEVA by quantifying human neuron EVs spiked into PBS at known concentrations. We first evaluated the assay qualitatively by examining the droplets under a microscope (Leica) (Figures 5A, S8). Assays run with increasing quantities of EVs showed an increase in the number of red fluorescent droplets that contain beads, each of these instances indicating a single detected targeted EV. Subsequently, we quantitatively analyzed the performance of DEVA by measuring the response of our μMD system to a serial dilution of human neuron EVs from 0–10⁵ EV/μL spiked into 100 μL PBS (Figure 5B). The
Figure 5. Benchmarking and characterization of DEVA. (A) Fluorescent microscopic images for DEVA assay on serial diluted human neuron EVs. (B) Calibration curve for DEVA detecting CD81/CD81 human neuron EVs spiked into PBS. Inset shows the detailed characterization. Error bars were calculated from experimental replicates (N = 3). (C) Signal over background for the calibration curve in A. Inset shows the zoomed-in view of signal-over-background (y-axis) from 0 to 4000 EVs (x-axis). (D) Analyzing more beads improves DEVA’s LOD by minimizing the background imprecision coming from Poisson noise. Inset shows that increasing overbackground (calibration curve in A. Inset shows the zoomed-in view of signal-indicated by gray bar). Inset shows detailed characterization. Error bars were calculated from experimental replicates (N = 3). (G) Signal over background for the calibration curve for DEVA in complex media. Inset shows the zoomed-in view from 0 to 5000 EVs/μL. (H) DEVA shows no significant difference (student t test) on the background level, when no EVs were spiked, was AEVBb = 0.026%, which is 8–40 times lower compared with typical dELISA.28,33 We quantified the LOD of DEVA for detecting targeted EVs in PBS as LOD = 9EVS/μL. Within the dynamic range (DR, 9×5 × 103 EVs/μL), DEVA showed good linearity (Figure 5C, R2 = 0.9976).

We directly evaluated the role of the number of beads used in a DEVA assay to reduce the Poisson noise in the measurement and thus improve the LOD. Using the same assay conditions, we calculated the AEVBb by analyzing 103 to 105 beads. As expected, analyzing more beads decreased the standard deviation of the measurement of the response to a blank input AEVBb, which decreased the LOD of DEVA (Figure 5D). We also compared the performance of DEVA with conventional EV characterization platforms NTA and Nanoview, using aliquots of the same samples processed by our μMD (Figure 59). NTA is a common tool for EV quantification and surface protein analysis.29 We found, consistent with the literature, the LOD for NTA is ∼O (104 EV/μL) with DR (104−2 × 104 EV/μL). Nanoview provides a multiplexed surface protein profiling of individual EVs. We quantified the LOD of Nanoview to be ∼O (103 EV/μL) and the DR to be 2.3 log range, similar to their commercial characterization(2.8 log). In comparison to these technologies, DEVA showed a 100x better LOD and a 200x better DR for single EV characterization (Figure 5E).

CHARACTERIZATION OF BACKGROUND INVARIANCE OF DEVA

We evaluated the performance of DEVA to quantify rare EVs in the presence of complex media. To this end, we spiked human neuron EVs into fetal bovine serum (FBS) that contained 2 × 107 bovine EVs as background (Figure S10), similar to the number of human EVs present in a 2 μL blood from a typical finger prick. We chose FBS because it models a complex background but does not contain any EVs positive for hum-CD81.24,30 We analyzed the performance of DEVA by measuring the response of our μMD system to a serial dilution of human neuron EVs from 0−106 EV/μL spiked into 100 μL FBS (Figure 5F). The LOD of DEVA in complex media is 11EVS/μL. DEVA demonstrated good linearity within the dynamic range (Figure 5G, R2 = 0.9996). We found that the bovine EV background did not have a significant effect on the LOD of DEVA compared to measurements in PBS (Figure 5H), demonstrating the potential of this technology to be applied to detecting rare EVs in clinical samples. Additionally, we demonstrated the feasibility of quantifying endogenous EVs in human plasma, using isotope antibodies for capture and labeling as a negative control (Figure S11).

DISCUSSION

Our DEVA platform with its high sensitivity (LOD = 9 EVs/μL) and its high droplet throughput (20 M droplets/min) makes it possible to quantify sparse EV subpopulations in complex media. The key to our device’s sensitivity is its processing of tens of millions of droplets, and its capability to scale its processing rate only at a cost in computation. While in this first demonstration we performed a single-plex assay to quantify EVs based on CD81/CD81 expression, we can combine our droplet throughput and a multicolor detection approach to analyze multiple EV subpopulations simultane-ously. Multiplexing can be increased by running assays in
parallel, using microbeads barcoded with distinct ratios of concentrations of multiple dyes, as has been done by Luminex for nondigital ELISA. Alternatively, or in combination, the sample can be divided to be mixed with different panels of microbeads in individual sets of channels of the n = 90 detection channels. By combining these two approaches, it is possible for DEVA to achieve >100 multiplexed EV assays. Recently, a growing number of studies has shown the clinical value of measuring <8 of EV subpopulations. In prior work, we describe a duplex protein assay as a starting point. In addition to EVs, our approach can be applied to quantify other nanoscale objects, such as mitochondria to study their dysfunction in Alzheimer’s disease or HIV virus to study transfection mechanisms. Additionally, we are encouraged by recent advances in digital assays, which either obviate the need for droplets by replacing enzymatic amplification with rolling circle amplification directly on beads or obviate the need for microfluidics by using beads that template droplets. These techniques, incorporated with DEVA, could provide a further 10x improvement in throughput and allow a simpler implementation, which can be leveraged to increase multiplexing, further improve sensitivity, and allow point-of-care use. In addition to improving the LOD, the throughput of our system can be leveraged to increase the LOD by reducing partitioning error at high concentrations of EVs, resulting in an increased dynamic range. By applying high throughput digital droplet detection to single EV analysis, the µMD allows ultrasensitive, multiplexed EV detection in complex media, opening a broad range of new possibilities for clinical diagnostics and biological inquiry.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.nanolett.2c00274.

Materials and methods for microfluidic device fabrication, optical setup, human neuron cell culture, preparation of antibody coated magnetic microbeads, detection antibody biotinylation, video processing and analysis, fabrication of 10-channel droplet microfluidics device, calculation of partitioning error; comparison between DEVA and typical commercial or research-based digital ELISA platforms, comparison between DEVA and typical commercial or research-based single EV analysis platforms, photograph of experimental setup, laser excitation characterization, DEVA fluorescence characterization, demonstration of parallelized droplet generators, SEM images of beads capturing individual EVs, protein quantification from isolated EVs, optimization of reagent concentrations for DEVA, microscopic images of fluorescent droplets, human neuron EV characterization using conventional tools, NTA analysis on isolated EVs, characterization of human plasma EVs on DEVA (PDF)

AUTHOR INFORMATION

Corresponding Author
David A. Issadore — Department of Bioengineering, School of Engineering and Applied Science and Department of Electrical and Systems Engineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States; orcid.org/0000-0002-5461-8653; Email: issadore@seas.upenn.edu

Authors
Zijian Yang — Department of Mechanical Engineering and Applied Mechanics, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Yasemin Atiyas — Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Hanfei Shen — Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Michael J. Siedlik — Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Jingyu Wu — Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Kryshawna Beard — Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Gennady Fonar — Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Jean Pierre Dolle — Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Douglas H. Smith — Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
James H. Eberwine — Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
David F. Meaney — Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Complete contact information is available at: https://pubs.acs.org/doi/10.1021/acs.nanolett.2c00274

Author Contributions
Z.Y., Y.A., and H.S. contributed equally to this work.

Funding
This work was supported by a grant from the Paul G. Allen Frontiers group (Grant 12347), the New Jersey Commission for Brain Injury Research, Grant W81XWH1920002 from the Department of Defense, grant RMI HG010023 from the National Institutes of Health, and Grant 5R21CA236653 from the National Cancer Institute. Y.A. is supported by a National Defense Science and Engineering Graduate Fellowship from the Department of Defense.

Notes
The authors declare the following competing financial interest(s): David Issadore is a founder and holds shares in the startup company Chip Diagnostics.

REFERENCES


